Population Pharmacokinetics of Antibiotics, Sedative and Analgesics, and Antiplatelet Agents During Extracorporeal Membrane Oxygenation (ECMO)

Gachon University Gil Medical Center1 site in 1 country10 target enrollmentJuly 16, 2019

ConditionsPharmacokinetics Extracorporeal Membrane Oxygenation

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pharmacokinetics
Sponsor: Gachon University Gil Medical Center
Enrollment: 10
Locations: 1
Primary Endpoint: Pharmacokinetic parameters
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to optimize the dosage regimen of drugs in patients during during Extracorporeal Membrane Oxygenation (ECMO) by population pharmacokinetic modeling.

Registry

clinicaltrials.gov

Start Date

July 16, 2019

End Date

July 15, 2024

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Gachon University Gil Medical Center

Responsible Party

Principal Investigator

Jin Wi

Director of Heart Intensive Care Unit

Gachon University Gil Medical Center

Eligibility Criteria

Inclusion Criteria

•Patients who are taking levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel while underdoing Extracorporeal Membrane Oxygenation

Exclusion Criteria

•Pregnant women
•Receiving a therapy that can affect blood concentration due to a drug-drug interaction with levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel